NEW YORK – Diagnostic developer Entopsis is taking its first steps into the cancer space by adapting its multi-analyte detection platform for prostate cancer screening and partnering with national laboratory Genetics Institute of America (GIA).

The Miami-based firm’s platform, called OpsisDx, uses a glass slide with 70 hydrogel structures that bind to molecules in a patient’s liquid sample and create a colorimetric signature when heated that reflect biometric changes in a patient’s body.

…

To continue reading, visit the full release on 360Dx.